Loading...
Loading...
ANEB| Name | Value |
|---|---|
| Revenues | 0.0K |
| Cost of Revenue | 0.0K |
| Gross Profit | 0.0K |
| Operating Expense | 2,543.7K |
| Operating I/L | -2,543.7K |
| Other Income/Expense | 62.9K |
| Interest Income | 55.2K |
| Pretax | -2,480.8K |
| Income Tax Expense | -57.7K |
| Net Income/Loss | -2,480.8K |
Anebulo Pharmaceuticals, Inc. is a clinical-stage biotechnology company specializing in developing and commercializing treatments for acute cannabinoid intoxication and substance addiction. The company's primary focus is on its lead product candidate, ANEB-001, a small molecule cannabinoid receptor antagonist designed to address cannabinoid intoxication and overdose.
